Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952875 | 1.00 | POLB (0.35) | POLBAGTR2ATMCYP1A2TDP1 | |
| SCHEMBL26694944 | 1.00 | POLB (0.35) | POLBAGTR2ATMCYP1A2TDP1 | |
| SCHEMBL27766883 | 0.90 | POLB (0.42) | POLBAGTR2ATMCYP1A2TDP1 | |
| SCHEMBL919018 | 0.83 | AGTR2 (0.47) | AGTR2ATM | |
| SCHEMBL8402776 | 0.83 | AGTR2 (0.47) | AGTR2ATM | |
| SCHEMBL6653686 | 0.83 | AGTR2 (0.47) | AGTR2ATM | |
| SCHEMBL1833567 | 0.81 | MMP2 (0.41) | POLBTSHR | |
| SCHEMBL28459854 | 0.80 | HSD17B10 (0.46) | MAPTLMNAHSD17B10 | |
| SCHEMBL20583848 | 0.80 | HSD17B10 (0.46) | MAPTLMNAHSD17B10 | |
| SCHEMBL7254080 | 0.80 | AGTR2 (0.35) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-116724044-A | Tri-heterocyclic compound, preparation method and application thereof | 上海湃隆生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022166749-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3786160-A1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10889568-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3700902-A1 | PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | POLB 4618/4885AGTR2 191/4885ATM 3967/4885 |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | POLB 4783/4885AGTR2 153/4885ATM 3807/4885 |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | POLB 4770/4885AGTR2 126/4885ATM 3604/4885 |
| US-10889568-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | POLB 4783/4885AGTR2 153/4885ATM 3807/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | POLB 4783/4885AGTR2 153/4885ATM 3807/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | POLB 4783/4885AGTR2 153/4885ATM 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.